Current progress in the study of acute myeloid leukemia

2019

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.26577/ijbch-2019-i2-11
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

In recent years the rate of malignant diseases has been growing rapidly around the world. The Republic of Kazakhstan, according to international statistics, refers to the countries with moderately high cancer incidence and mortality. Every year approximately thirty thousand Kazakhstani people are diagnosed with cancer. In 2018, 35,753 patients were registered in the country, of which 44.3% were men and 55.7% were women. Cancer mortality over the same period amounts to about 15,000 lives. The cancer incidence rate increased by 8% from 181.2 (in 1999) to 195.7 per 100,000 population in 2019 [1]. Blood cancers are relatively rare diseases but, nevertheless, in Kazakhstan about 7,000 patients with hematopoietic malignancies are currently registered. Therefore, our knowledge of recent advances in hemato-oncology is highly relevant for successful therapy of these malignancies. In this review we provide information on the subtypes, symptoms, diagnosis and treatment of acute myeloid leukemia (AML) – one of the most aggressive blood cancer.